T cell receptor-like antibodies specific for Foxp3-derived peptides

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11505599
APP PUB NO 20190284262A1
SERIAL NO

16069999

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The presently disclosed subject matter provides antigen-binding proteins (e.g., chimeric antigen receptors) and antibodies or antigen-binding portions thereof that bind to a Foxp3 peptide/MHC molecule complex. Such antibodies, fusion proteins and conjugates thereof are useful for inhibiting regulatory T cells and treating cancers.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • MEMORIAL SLOAN KETTERING CANCER CENTER; EUREKA THERAPEUTICS, INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Dao, Tao New York, US 15 121
Liu, Cheng Emeryville, US 232 905
Scheinberg, David A New York, US 62 1083

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 May 22, 2026
7.5 Year Payment $3600.00 $1800.00 $900.00 May 22, 2030
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 22, 2034
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00